Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 12/20 | 0.41 |
| ▸ | FNTB | P49356 | 12/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24490179 | 1.00 | KIF11 (0.50) | KIF11FNTAFNTBPKMESR1 | |
| SCHEMBL24490183 | 1.00 | KIF11 (0.50) | KIF11FNTAFNTBPKMESR1 | |
| SCHEMBL22460962 | 0.87 | KIF11 (0.48) | KIF11FNTAFNTBESR1ESR2 | |
| SCHEMBL22460956 | 0.87 | KIF11 (0.48) | KIF11FNTAFNTBESR1ESR2 | |
| SCHEMBL22461271 | 0.87 | KIF11 (0.55) | KIF11ESR1ESR2 | |
| SCHEMBL22461269 | 0.87 | KIF11 (0.55) | KIF11ESR1ESR2 | |
| SCHEMBL24490035 | 0.80 | KIF11 (0.44) | KIF11FNTAFNTBESR1ESR2 | |
| SCHEMBL24490034 | 0.80 | KIF11 (0.44) | KIF11FNTAFNTBESR1ESR2 | |
| SCHEMBL22445601 | 0.80 | KIF11 (0.44) | KIF11FNTAFNTBESR1ESR2 | |
| SCHEMBL22461281 | 0.78 | KIF11 (0.45) | KIF11ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941905-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |